Professor of neurology and director, Translational Imaging Center, Clinical Translational Research Center, Buffalo Neuroimaging Analysis Center, and director, Buffalo Neuroimaging Analysis Center.
Overcoming Issues With Access to MRIs, Resources in Care of Multiple Sclerosis: Robert Zivadinov, MD, PhDMarch 6th 2023
The director of the Buffalo Neuroimaging Analysis Center provide perspective on innovative ways to monitor progression in multiple sclerosis, and the importance of high-level care facilities. [WATCH TIME: 5 minutes]
Assessing Deep Gray Matter Loss in Cortical, Thalamic Regions to Understand MS Progression: Robert Zivadinov, MD, PhDMarch 2nd 2023
The director of the Buffalo Neuroimaging Analysis Center discussed the need to further explain differences in cortical lesions and deep gray matter in patients with severely affected multiple sclerosis. [WATCH TIME: 4 minutes]
Differentiating Severe Multiple Sclerosis Through a Comprehensive Assessment: Robert Zivadinov, MD, PhDFebruary 28th 2023
The director of the Buffalo Neuroimaging Analysis Center provided context on the CASA-MS study, and the key differences in why certain patients with multiple sclerosis experience more rapid disability progression. [WATCH TIME: 4 minutes]
Ocrelizumab’s Impact on Humoral Response to EBV: Robert Zivadinov, MD, PhDNovember 1st 2022
The director of the Buffalo Neuroimaging Analysis Center provided context on a new study exploring ocrezliumab’s (Ocrevus; Genentech) effect on leptomeningeal inflammation and humoral response to EBV. [WATCH TIME: 5 minutes]
Comparing Reactive Microglia and Astrocytes in Secondary Progressive Multiple SclerosisApril 25th 2022
Robert Zivadinov, MD, PhD, discusses the design of a novel comparative study assessing the effect of siponimod (Mayzent; Novartis) and ocrelizumab (Ocrevus; Genentech) on microglia and astrocytes in patients with SPMS.